Anika Therapeutics, Inc.
ANIK
$11.08
-$0.19-1.69%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -7.95% | -- | -354.96% | 96.79% | 56.39% |
| Total Depreciation and Amortization | -22.83% | -- | -38.23% | -42.03% | -41.90% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -47.42% | -- | 414.13% | 11.38% | 156.16% |
| Change in Net Operating Assets | 93.56% | -- | -56.63% | 40.84% | -750.93% |
| Cash from Operations | -3.17% | -- | -22.65% | 87.11% | 96.52% |
| Capital Expenditure | -56.19% | -- | -64.10% | -133.56% | -30.17% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 192.48% | -- | -145.07% | -133.56% | -30.17% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -4.53% | 228.57% |
| Repurchase of Common Stock | -136.85% | -- | -3,528.18% | 70.99% | -41.73% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -139.24% | -- | -3,528.18% | 77.52% | -40.92% |
| Foreign Exchange rate Adjustments | 448.39% | -- | 724.07% | -929.63% | -203.33% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 10.62% | -- | -108.14% | 60.41% | 35.69% |